Hydrochloric Acid → N-{4-Methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(pentafluoro-lambda6-sulphanyl)-5-(piperazin-1-yl)benzamide

HRID 1055714노트

반응식

HRID 1055714 반응식
CC1C=CC(N)=CC=1N1C2N(N=C(C3C=NC=CC=3)C=2)C=C1.C(OC(N1CCN(C2C=C(C=C(S(F)(F)(F)(F)F)C=2)C(O)=O)CC1)=O)(C)(C)C.[CH3:51][C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:59]([C:61]2[CH:62]=[C:63]([N:73]3[CH2:78][CH2:77][N:76](C(OC(C)(C)C)=O)[CH2:75][CH2:74]3)[CH:64]=[C:65]([S:67]([F:72])([F:71])([F:70])([F:69])[F:68])[CH:66]=2)=[O:60])=[CH:54][C:53]=1[N:86]1[C:93]2[N:89]([N:90]=[C:91]([C:94]3[CH:95]=[N:96][CH:97]=[CH:98][CH:99]=3)[CH:92]=2)[CH:88]=[CH:87]1.Cl>O1CCOCC1.CO>[CH3:51][C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:59](=[O:60])[C:61]2[CH:62]=[C:63]([N:73]3[CH2:74][CH2:75][NH:76][CH2:77][CH2:78]3)[CH:64]=[C:65]([S:67]([F:71])([F:70])([F:69])([F:72])[F:68])[CH:66]=2)=[CH:54][C:53]=1[N:86]1[C:93]2[N:89]([N:90]=[C:91]([C:94]3[CH:95]=[N:96][CH:97]=[CH:98][CH:99]=3)[CH:92]=2)[CH:88]=[CH:87]1

참가 물질

7

반응 조건

온도
80 °C

실험 절차

120 mg (0.42 mmol) of the compound of Example 6A and 179 mg (0.42 mmol) of the compound of Example 16A were reacted and worked up analogously to the procedure of Example 16. In this manner, 260 mg (89% of theory) of the Boc-protected intermediate tert-butyl 4-[3-({4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}carbamoyl)-5-(pentafluoro-λ6-sulphanyl)-phenyl]piperazine-1-carboxylate were obtained. This compound was dissolved in 3 ml of 1,4-dioxane and 1 ml of methanol, 0.31 ml (1.24 mmol) of a 4 M solution of hydrogen chloride in 1,4-dioxane was added and the mixture was stirred at 80° C. for 1 h. The mixture was then concentrated under reduced pressure and the residue was purified by preparative HPLC (Method 18). The product fractions were concentrated and the residue was dissolved in ethyl acetate and washed successively with saturated potassium carbonate solution and saturated sodium chloride solution. The organic phase was dried over sodium sulphate, filtered and concentrated under reduced pressure. Drying of the residue gave 155 mg (62% of theory) of the title compound.

후처리

  1. customwere obtained
  2. concentrationThe mixture was then concentrated under reduced pressure
  3. customthe residue was purified by preparative HPLC (Method 18)
  4. concentrationThe product fractions were concentrated
  5. dissolutionthe residue was dissolved in ethyl acetate
  6. washwashed successively with saturated potassium carbonate solution and saturated sodium chloride solution
  7. dry with materialThe organic phase was dried over sodium sulphate
  8. filtrationfiltered
  9. concentrationconcentrated under reduced pressure
  10. customDrying of the residue

출처 및 근거

ORD 기록
ord-ab86ac06e4c04ce5bd3d7695349ecd19
출처 데이터셋
uspto-grants-2016_07
특허 번호
US09394309B2

반응 노트

불러오는 중…